The Food and Drug Administration approved Pfizer's treatment for a rare genetic bleeding disorder, making it the company's first gene therapy to win clearance in the U.S. The agency greenlighted the ...

Biogen Idec is in the news again; on July 4, 2013 the company presented new data in support of clinical and safety profile for ELOCTATE, its candidate for hemophilia A that it is developing in ...

Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. The hemophilia A treatment could ...

A one-time novel gene therapy can reduce the risk of excessive bleeding in people with the bleeding disorder hemophilia B, who typically would need repeat therapies to reduce their risk, according to ...

Hemophilia is a genetic condition that can’t be prevented. Modern medical treatments can help prevent bleeding and increase life span. Hemophilia is a rare genetic condition that affects how your ...

Hemophilia is a rare and often misunderstood disease. Many people only know that it's a blood disorder, and after that, myths and misinformation abound. So what exactly is hemophilia? Alisa Wolberg, ...

Hemophilia is a blood clotting disorder that can be inherited. Caused by changes in the X chromosome, hemophilia is an X-linked recessive disorder. Hemophilia is a genetic disorder that affects the ...

Hemophilia is an inherited bleeding disorder caused by deficiency of coagulation factor VIII (haemophilia A) or IX (haemophilia B). Traditional management relies on regular intravenous infusions of ...

Hemophilia A and B are similar conditions that affect the blood’s ability to clot. They typically occur due to gene variations that affect different blood clotting factors. Hemophilia is a group of ...

A soon-to-be-released documentary film aims to change the conversation around hemophilia, a condition in which many female patients go misdiagnosed for years and often feel ignored or overlooked by ...